Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa R. Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 19(9), DOI: https://doi.org/10.1016/s1470-2045(18)30379-6.